INS and Alzheimer disease: Summary of fluorine-labelled fluorodeoxyglucose ([18F]-FDG) studies evaluating the effect of Alzheimer’s disease (AD), mild cognitive impairment (MCI), aging, obesity, and insulin resistance (IR) on brain glucose metabolism during fasting and insulin clamp #.